COMPARE · Data as of August 27, 2026
EXEL vs NKTR
Verdict: Side-by-side breakdown using the Bull Rankings model. EXEL scored 73.9, NKTR scored 25.8 — EXEL leads.
Compare another set
EXEL
Exelixis, Inc.
73.9
$56.72 · $14.1B
fundamentals as of
Score gap
48.1
EXEL leads
NKTR
Nektar Therapeutics
25.8
$74.55 · $2.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthEXEL+9.2%
- Strongest balance sheetEXEL0.09
- Highest qualityEXEL97 / 100
- Largest discount to fair valueEXEL-39%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
EXEL
stronger →← stronger
NKTR
97
Qualityreturns · margins · balance sheet
18
80
Growthrevenue & earnings expansion
14
52
Valuevaluation vs sector peers
69
EXEL is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
EXEL
NKTR
$1.2bC+
FCF
-$234mF
+9.2%B
Rev
-43.9%F
0.09B+
D/E
0.15B+
17.8xA-
P/E
—
2.56C
PEG
0.31A
—
P/S
46.6xD
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
EXEL
NKTR
39% below
Price vs fair valuelower is cheaper
—
~-2%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+38%
1-yr DCF upside
—
+64%
5-yr DCF upside
—
+108%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EXEL
Why this score
- Buying back stock
- Durable high returns
NKTR
Why this score
- Diluting shareholders
The companies
EXELExelixis, Inc.
Why now
Biotechnology · market cap $14.1b. Trading near 52-week high of $57.57 — momentum setup, limited technical margin of safety. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -7% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
NKTRNektar Therapeutics
Why now
Biotechnology · market cap $2.5b. Down 32% from 52-week high of $109.00 — deep drawdown territory. Revenue -44% — in contraction; any catalyst that reverses this triggers re-rating. PEG 0.31 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $144.40 (implying +94% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$234m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -44% — the operational turn is not yet visible in the top line. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where EXEL and NKTR diverge
On the headline score the gap is 48.1 points in favor of EXEL. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityEXEL 96.8 · NKTR 18.0EXEL +78.8
- GrowthEXEL 80.0 · NKTR 13.8EXEL +66.2
- ValueEXEL 52.2 · NKTR 69.0NKTR +16.8
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.